



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/643,699
				Filing Date	August 18, 2003
				First Named Inventor	Pascal Druzgala
				Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	ARYX-112XCD1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code* (if known)			
K	U1	US-4,808,605	02-28-1989	Branca <i>et al.</i>	All
K	U2	US-5,620,975	04-15-1997	Clozel <i>et al.</i>	All
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T*
		Country Code ²	- Number ³ - Kind Code ⁴ (if known)				
K	F1	EP	0 524 512 A2	01-27-1993	F. HOFFMANN-LA ROCHE AG	All	
	F2	JP	11 035483 A (Abstract only)	02-09-1999	NIPPON KAYAKU CO. LTD.	All	
	F3						
	F4						
	F5						
	F6						
	F7						
	F8						
	F9						
	F10						

Examiner Signature	<i>S. H. K.</i>	Date Considered	<i>02/04/05</i>
--------------------	-----------------	-----------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Information Freedom Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/643,699
		Filing Date	August 18, 2003
		First Named Inventor	Pascal Druzgala
		Group Art Unit	
		Examiner Name	
Sheet	2	of	2
		Attorney Docket Number	ARYX-112XCD1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
K	R1	Bursztyn, M., et al., "Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: Favorable hemodynamics and pharmacokinetics", <i>American Heart Journal</i> , August 1997, pp. 238-47, Vol. 134, No. 2, Pt. 1, Mosby-Year Book, Inc.	
K	R2	De Ponti, F., et al., "QT-Interval prolongation by non-cardiac drugs: lessons to be learned from recent experience", <i>Eur J Clin Pharmacol</i> , 2000, pp. 1-18, Vol. 56, Springer-Verlag.	
K	R3	Dershwitz, M., et al. "Pharmacokinetics and Pharmacodynamics of Remifentanyl in Volunteer Subjects with Severe Liver Disease", <i>Anesthesiology</i> , April 1996, pp. 812-20, Vol. 84, No. 4, American Society of Anesthesiologists, Inc., Lippincott-Raven Publishers.	
K	R4	Kostrubsky, V., et al., "The Role of Conjugation in Hepatotoxicity of Troglitazone in Human and Porcine Hepatocyte Cultures", <i>Drug Metabolism and Disposition</i> , 2000, pp. 1192-97, Vol. 28, No. 10, The American Society for Pharmacology and Experimental Therapeutics.	
19	R5	RUTLEDGE et al. "The Binding Interactions of Ro 40-5967 at the L-type Ca ²⁺ Channel in Cardiac Tissue" <i>European Journal of Pharmacology</i> , 1995, pp. 155-158, Vol. 280.	
K	R6	Selnick, H., et al., "Class-III Antiarrhythmic Activity in Vivo By Selective Blockade of the Slowly Activating Cardiac Delayed Rectifier Potassium Current <i>I_{Ks}</i> by (R)-2-(2,4-Trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-2,3-dihydro-1H-benzo[e][1,4] diazepin-3-yl] acetamide," <i>J. Med. Chem.</i> , November 1997, pp. 3865-8, Vol. 40, No. 24, American Chemical Society.	
K	R7	Vandenberg, J., et al., "HERG K ⁺ channels: friend and foe", <i>Trends in Pharmacological Sciences</i> , May 2001, pp. 240-6, Vol. 22, No. 5, Elsevier Science, Ltd.	
	R8		
	R9		
	R10		
	R11		
	R12		

Examiner Signature	<i>St. H. K.</i>	Date Considered	02/04/03
--------------------	------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

† Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.